Topics

Bristol-Myers Squibb & Sanofi-aventis Company Profile

13:03 EST 13th November 2019 | BioPortfolio

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE:SNY) . For more information, www.sanofi-aventis.us or www.sanofi-aventis.com.


News Articles [1348 Associated News Articles listed on BioPortfolio]

Catalent to Buy Bristol-Myers' Factory in Italy, Adding to Latest String of Expansions

The facility has acted as one of Bristol-Myers Squibb’s primary launch facilities for new drugs. After the deal is closed, Catalent will continue to manufacture Bristol-Myers Squibb’s current prod...

Catalent To Buy Bristol-Myers Squibb's Manufacturing Facility In Italy

NEW YORK CITY (dpa-AFX) - Catalent, Inc. (CTLT) has agreed to purchase Bristol-Myers Squibb's manufacturing and packaging facility in Anagni, Italy. Bristol-Myers Squibb plans to maintain a contin...

Bristol-Myers Squibb Voluntarily Recalls One Lot of Eliquis (apixaban) 5 mg Tablets

Bristol-Myers Squibb Company (NYSE: BMY) is voluntarily recalling one lot (#HN0063) of Eliquis 5 mg tablets to the consumer level. This lot was distributed nationwide in the U.S. to wholesalers and re...

Bristol-Myers plant Verkauf für Celgene-Übernahme: Besonders im Bereich Schuppenflechte würden Bristol-Myers ...

Besonders im Bereich Schuppenflechte würden Bristol-Myers Squibb und Celgene große Marktanteile konsolidieren. Die Pharmakonzerne sind kompromissbereit.Der US-Pharmakonzern Bristol-Myers Squibb arb....

FTC Seeks Additional Information On Bristol-Myers - Celgene Merger

SUMMIT (dpa-AFX) - Bristol-Myers Squibb Co.(BMY) disclosed in Tuesday regularly fling that On March 25, 2019, Bristol-Myers Squibb and Celgene each received a request for additional information an...

Bristol-Myers Squibb to Take Part at the Morgan Stanley Conference

Bristol-Myers Squibb Company (NYSE: BMY) will take part in a fireside chat at the Morgan Stanley Conference on Monday, September 9, 2019, in New York. Giovanni Caforio, M.D., chairman and chief execu...

Bristol-Myers Squibb Boosts FY19 Adj. EPS Outlook

NEW YORK CITY (dpa-AFX) - While reporting financial results for the third quarter on Thursday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) slashed its earnings guidance for the full-y...

Bristol-Myers Squibb to Take Part at the Wolfe Research Healthcare Conference

Bristol-Myers Squibb Company (NYSE: BMY) will take part in a fireside chat at the Wolfe Research Healthcare Conference on Wednesday, November 6, 2019, in New York. Giovanni Caforio, M.D., chairman an...

Drugs and Medications [161 Associated Drugs and Medications listed on BioPortfolio]

Entecavir [accord healthcare inc.]

These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS . ENTECAVIR tablets, for oral use Ini...

Entecavir [golden state medical supply inc.]

ENTECAVIR TABLETS These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS . ENTECAVIR tablets...

Eloxatin [aventis pharma ltd.]

NA

Plavix [bristol-myers squibb/sanofi pharmaceuticals partnership]

These highlights do not include all the information needed to use PLAVIX safely and effectively. See full prescribing information for PLAVIX.   PLAVIX (clopidogrel bisulfate) tablets, for oral use In...

Entecavir [avkare, inc.]

Entecavir Tablets These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS. ENTECAVIR tablets,...

PubMed Articles [162 Associated PubMed Articles listed on BioPortfolio]

Storm warning: lung disease in systemic juvenile idiopathic arthritis.

Dr. Nigrovic's work was supported by the NIH grants R01 AR065538, AR075906, AR073201 and P30 AR070253, the Fundación Bechara and the Arbuckle Family Fund for Arthritis Research. PAN is the recipient ...

AMCP Partnership Forum: Integrated Delivery Networks' Role in Pharmaceutical Value-Based Agreements.

Health care payment models that reward value over volume have the potential to improve patient care and control rising costs. These payment models are increasingly being implemented by a range of care...

A Randomized, Single-dose, Two-sequence, Two-period, Crossover Study to assess the Bioequivalence between Two Formulations of Clonazepam Tablet in Healthy Subjects.

Clonazepam is a benzodiazepine commonly prescribed to treat panic disorder, epilepsy, anxiety, depression and certain types of seizures. This study aimed to evaluate the bioequivalence between two for...

LAG-3 antagonists by cancer treatment: a patent review.

: LAG-3 is checkpoint inhibitor in cancer that coordinates the down regulation of the proliferation of antigen-specific lymphocytes. There is a great need to discover and develop new therapies focused...

Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer.

Targeting programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) immunologic checkpoint blockade with monoclonal antibodies has achieved recent clinical success in antitumor therapy....

Clinical Trials [183 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Daclatasvir From Prodactariv 60 mg Film Coated Tablets (International Drug Agency for Pharmaceutical Industry (IDI), Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Prodactariv 60 mg F.C.T (International Drug Agency for Pha...

Food Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg

The objective of this study was to investigate the bioequivalence of Mylan's clopidogrel bisulfate 75 mg tablets to Bristol-Myers Squibb/Sanofi's Plavix® 75 mg tablets following a single,...

Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Daktavira 60 mg film coated tablets ( European Egyptian Ph...

Fasting Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg

The objective of this study was to investigate the bioequivalence of Mylan's clopidogrel bisulfate 75 mg tablets to Bristol-Myers Squibb/Sanofi's Plavix® 75 mg tablets following a single,...

Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects

- Objective: - A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Co...

Companies [194 Associated Companies listed on BioPortfolio]

Bristol-Myers Squibb & Sanofi-aventis

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the l...

sanofi-aventis/Bristol-Myers Squibb Partnership

Pfizer Inc. & Bristol-Myers Squibb

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

Bristol-Myers Squibb and Pfizer

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

Bristol-Myers Squibb Company and Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize Eliquis, an oral anticoagulant discovered by Bristol-Myers Squibb. Thi...

More Information about "Bristol-Myers Squibb & Sanofi-aventis" on BioPortfolio

We have published hundreds of Bristol-Myers Squibb & Sanofi-aventis news stories on BioPortfolio along with dozens of Bristol-Myers Squibb & Sanofi-aventis Clinical Trials and PubMed Articles about Bristol-Myers Squibb & Sanofi-aventis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Bristol-Myers Squibb & Sanofi-aventis Companies in our database. You can also find out about relevant Bristol-Myers Squibb & Sanofi-aventis Drugs and Medications on this site too.

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Corporate Database Quicklinks



Searches Linking to this Company Record